SK17332000A3 - Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby - Google Patents

Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby Download PDF

Info

Publication number: SK17332000A3
Authority: SK; Slovakia
Prior art keywords: tcr; peptide; protein; chains; recombinant
Prior art date: 1998-05-19

Application number

SK1733-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Bent Karsten Jakobsen

John Irving Bell

George Fu Gao

Benjamin Ernest Willcox

Jonathan Michael Boulter

Original Assignee

Avidex Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-19

Filing date

1999-05-19

Publication date

2001-06-11

1998-05-19 Priority claimed from GBGB9810759.2A external-priority patent/GB9810759D0/en

1998-09-29 Priority claimed from GBGB9821129.5A external-priority patent/GB9821129D0/en

1999-05-19 Application filed by Avidex Limited filed Critical Avidex Limited

2001-06-11 Publication of SK17332000A3 publication Critical patent/SK17332000A3/sk

Links

108091008874 T cell receptors Proteins 0.000 title claims abstract description 389
102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 380
238000000034 method Methods 0.000 claims abstract description 49
239000003814 drug Substances 0.000 claims abstract description 9
229940124597 therapeutic agent Drugs 0.000 claims abstract description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 97
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 42
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 41
108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
230000014509 gene expression Effects 0.000 claims description 34
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 31
102100023132 Transcription factor Jun Human genes 0.000 claims description 31
239000000872 buffer Substances 0.000 claims description 29
239000000833 heterodimer Substances 0.000 claims description 28
238000006471 dimerization reaction Methods 0.000 claims description 27
102000004196 processed proteins & peptides Human genes 0.000 claims description 27
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 26
241000588724 Escherichia coli Species 0.000 claims description 23
239000004202 carbamide Substances 0.000 claims description 22
238000005734 heterodimerization reaction Methods 0.000 claims description 21
239000012528 membrane Substances 0.000 claims description 20
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 13
210000004899 c-terminal region Anatomy 0.000 claims description 13
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
239000013604 expression vector Substances 0.000 claims description 11
238000000338 in vitro Methods 0.000 claims description 10
150000007523 nucleic acids Chemical group 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
239000003638 chemical reducing agent Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
230000001086 cytosolic effect Effects 0.000 claims description 4
230000003308 immunostimulating effect Effects 0.000 claims description 3
229940127089 cytotoxic agent Drugs 0.000 claims description 2
230000009258 tissue cross reactivity Effects 0.000 claims 25
239000013578 denaturing buffer Substances 0.000 claims 2
102100027584 Protein c-Fos Human genes 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
230000027455 binding Effects 0.000 abstract description 47
108090000623 proteins and genes Proteins 0.000 description 122
102000004169 proteins and genes Human genes 0.000 description 114
235000018102 proteins Nutrition 0.000 description 109
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 69
235000005772 leucine Nutrition 0.000 description 63
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 62
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 62
210000004027 cell Anatomy 0.000 description 60
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 50
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 41
206010022000 influenza Diseases 0.000 description 41
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 39
239000013615 primer Substances 0.000 description 39
229960002685 biotin Drugs 0.000 description 37
239000011616 biotin Substances 0.000 description 37
235000020958 biotin Nutrition 0.000 description 36
239000000499 gel Substances 0.000 description 31
238000007413 biotinylation Methods 0.000 description 28
230000006287 biotinylation Effects 0.000 description 28
239000007983 Tris buffer Substances 0.000 description 26
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 26
108010074032 HLA-A2 Antigen Proteins 0.000 description 25
102000025850 HLA-A2 Antigen Human genes 0.000 description 25
230000035772 mutation Effects 0.000 description 25
239000011780 sodium chloride Substances 0.000 description 25
108091007433 antigens Proteins 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
239000000427 antigen Substances 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
230000003993 interaction Effects 0.000 description 22
210000001744 T-lymphocyte Anatomy 0.000 description 21
239000012634 fragment Substances 0.000 description 20
239000003446 ligand Substances 0.000 description 20
239000000203 mixture Substances 0.000 description 20
239000000243 solution Substances 0.000 description 18
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 17
210000003000 inclusion body Anatomy 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
210000000612 antigen-presenting cell Anatomy 0.000 description 16
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 16
230000004044 response Effects 0.000 description 16
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 15
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
229960004198 guanidine Drugs 0.000 description 15
238000000746 purification Methods 0.000 description 15
230000000694 effects Effects 0.000 description 14
230000004927 fusion Effects 0.000 description 14
239000011159 matrix material Substances 0.000 description 14
239000000047 product Substances 0.000 description 13
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 13
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
238000004458 analytical method Methods 0.000 description 12
230000006870 function Effects 0.000 description 12
125000003275 alpha amino acid group Chemical group 0.000 description 11
238000010828 elution Methods 0.000 description 11
239000011550 stock solution Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
108060003951 Immunoglobulin Proteins 0.000 description 10
108010090804 Streptavidin Proteins 0.000 description 10
238000013461 design Methods 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
102000037865 fusion proteins Human genes 0.000 description 10
102000018358 immunoglobulin Human genes 0.000 description 10
239000013598 vector Substances 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000012505 Superdex™ Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
235000018417 cysteine Nutrition 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
108010003486 leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine Proteins 0.000 description 9
108060003393 Granulin Proteins 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
239000000463 material Substances 0.000 description 8
238000005259 measurement Methods 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
230000009870 specific binding Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
108020001019 DNA Primers Proteins 0.000 description 7
239000003155 DNA primer Substances 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 7
241000283984 Rodentia Species 0.000 description 7
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 7
239000008188 pellet Substances 0.000 description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
239000000523 sample Substances 0.000 description 7
238000010186 staining Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108010024636 Glutathione Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
235000018936 Vitellaria paradoxa Nutrition 0.000 description 6
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
238000011068 loading method Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
239000000758 substrate Substances 0.000 description 6
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
238000001712 DNA sequencing Methods 0.000 description 5
108010053070 Glutathione Disulfide Proteins 0.000 description 5
241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
102000043129 MHC class I family Human genes 0.000 description 5
108091054437 MHC class I family Proteins 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000010276 construction Methods 0.000 description 5
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 5
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
238000011534 incubation Methods 0.000 description 5
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
238000012546 transfer Methods 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
108010076804 DNA Restriction Enzymes Proteins 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
102000011931 Nucleoproteins Human genes 0.000 description 4
108010061100 Nucleoproteins Proteins 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
238000005349 anion exchange Methods 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000004925 denaturation Methods 0.000 description 4
230000036425 denaturation Effects 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000000926 separation method Methods 0.000 description 4
241000894007 species Species 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
102000043131 MHC class II family Human genes 0.000 description 3
108091054438 MHC class II family Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
101100112779 Mus musculus Cd247 gene Proteins 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000007792 addition Methods 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
238000000137 annealing Methods 0.000 description 3
108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
102000015736 beta 2-Microglobulin Human genes 0.000 description 3
108010081355 beta 2-Microglobulin Proteins 0.000 description 3
108091006004 biotinylated proteins Proteins 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000000539 dimer Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000037432 silent mutation Effects 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000014616 translation Effects 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108010032795 CD8 receptor Proteins 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108020004485 Nonsense Codon Proteins 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
108010002747 Pfu DNA polymerase Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
101710100170 Unknown protein Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 2
108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
229910001870 ammonium persulfate Inorganic materials 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
229940099500 cystamine Drugs 0.000 description 2
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
239000003398 denaturant Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
125000002228 disulfide group Chemical group 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000001641 gel filtration chromatography Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000007429 general method Methods 0.000 description 2
229960000789 guanidine hydrochloride Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
230000006872 improvement Effects 0.000 description 2
108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
108010014346 influenza virus membrane protein (58-66) Proteins 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
229960003151 mercaptamine Drugs 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
238000011176 pooling Methods 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
239000012137 tryptone Substances 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
ZVEUWSJUXREOBK-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.OC[C@H](N)C(O)=O ZVEUWSJUXREOBK-DKWTVANSSA-N 0.000 description 1
SHWZFPFHYGKWIW-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;3-hydroxypyrrolidine-2,5-dione Chemical compound OC1CC(=O)NC1=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 SHWZFPFHYGKWIW-UFLZEWODSA-N 0.000 description 1
101710191936 70 kDa protein Proteins 0.000 description 1
101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
101001124039 Banna virus (strain Indonesia/JKT-6423/1980) Non-structural protein 4 Proteins 0.000 description 1
241001609030 Brosme brosme Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101001023124 Drosophila melanogaster Myosin heavy chain, non-muscle Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
102000011786 HLA-A Antigens Human genes 0.000 description 1
108010075704 HLA-A Antigens Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 1
101000659324 Homo sapiens Twinfilin-1 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108010000591 Myc associated factor X Proteins 0.000 description 1
101710150912 Myc protein Proteins 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000012435 analytical chromatography Methods 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
108010019077 beta-Amylase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
-1 biotin ester Chemical class 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000010612 desalination reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
102000050945 human TWF1 Human genes 0.000 description 1
108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000003367 kinetic assay Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
150000002614 leucines Chemical class 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229910001453 nickel ion Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229930192851 perforin Natural products 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
230000005313 thymus development Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biophysics (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1733-2000A 1998-05-19 1999-05-19 Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby SK17332000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9810759.2A GB9810759D0 (en)	1998-05-19	1998-05-19	Soluble t cell receptor
GBGB9821129.5A GB9821129D0 (en)	1998-09-29	1998-09-29	Multimeric T cell receptor
PCT/GB1999/001588 WO1999060120A2 (en)	1998-05-19	1999-05-19	Soluble t cell receptor

Publications (1)

Publication Number	Publication Date
SK17332000A3 true SK17332000A3 (sk)	2001-06-11

Family

ID=26313710

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1733-2000A SK17332000A3 (sk)	1998-05-19	1999-05-19	Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby

Country Status (27)

Country	Link
US (4)	US20020119149A1 (de)
EP (2)	EP1080193A2 (de)
JP (2)	JP2002515243A (de)
KR (2)	KR100530309B1 (de)
CN (2)	CN1249229C (de)
AT (1)	ATE208819T1 (de)
AU (2)	AU758949B2 (de)
BG (1)	BG105053A (de)
BR (1)	BR9910253A (de)
CA (2)	CA2328144A1 (de)
DE (1)	DE69900468T2 (de)
DK (1)	DK1066380T3 (de)
EA (1)	EA200001216A1 (de)
EE (1)	EE200000697A (de)
ES (1)	ES2168866T3 (de)
HR (1)	HRP20000790A2 (de)
HU (1)	HUP0103614A2 (de)
ID (1)	ID28040A (de)
IL (2)	IL139344A0 (de)
IS (1)	IS5697A (de)
NO (2)	NO20005812L (de)
NZ (2)	NZ507887A (de)
PL (1)	PL364734A1 (de)
PT (1)	PT1066380E (de)
SK (1)	SK17332000A3 (de)
TR (1)	TR200003391T2 (de)
WO (2)	WO1999060120A2 (de)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999060120A2 (en) *	1998-05-19	1999-11-25	Avidex Limited	Soluble t cell receptor
EP1118661A1 (de) *	2000-01-13	2001-07-25	Het Nederlands Kanker Instituut	T-Zellrezeptor-Bibliotheken
EP1287363A2 (de) *	2000-05-25	2003-03-05	Sunol Molecular Corporation	Modulation von wechselwirkungen in t-zellrezeptoren
IL160359A0 (en)	2001-08-31	2004-07-25	Avidex Ltd	Soluble t cell receptor
WO2003033520A2 (en)	2001-09-24	2003-04-24	University Of Pittburgh Of The Commonwealth System Of Higher Education	Anticancer vaccine and diganostic methods and reagents
US8623822B2 (en)	2002-03-01	2014-01-07	Bracco Suisse Sa	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003278807A1 (en)	2002-03-01	2004-08-13	Bracco International B.V.	Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en)	2002-03-01	2007-05-01	Bracco International B.V.	Multivalent constructs for therapeutic and diagnostic applications
CA2477935C (en) *	2002-03-01	2015-01-06	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en)	2002-03-01	2010-09-14	Bracco International B.V.	Targeting vector-phospholipid conjugates
US7261876B2 (en)	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
AU2003283963A1 (en)	2002-09-27	2004-04-19	Ludwig Institute For Cancer Research	Mage-c2 antigenic peptides and uses thereof
CA2501870C (en) *	2002-10-09	2013-07-02	Avidex Limited	Single chain recombinant t cell receptors
PT1558643E (pt) *	2002-11-09	2009-08-24	Immunocore Ltd	Apresentação de um receptor das células t
GB0227351D0 (en) *	2002-11-22	2002-12-31	Isis Innovation	Soluble T-cell receptors
EP1567553A2 (de) *	2002-12-03	2005-08-31	Avidex Ltd.	Rezeptorenkomplexe
GB0304068D0 (en) *	2003-02-22	2003-03-26	Avidex Ltd	Substances
WO2005001117A1 (ja)	2003-06-27	2005-01-06	Haruo Sugiyama	Ｗｔ１ワクチン適応患者の選択方法
KR101131297B1 (ko)	2003-11-10	2012-03-30	알토 바이오사이언스 코포레이션	가용성 티씨알 분자 및 이용 방법
US9090673B2 (en)	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20060014941A1 (en) *	2003-12-22	2006-01-19	University Of Tennessee Research Foundation, Inc.	Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
GB0411125D0 (en) *	2004-05-19	2004-06-23	Avidex Ltd	Method of improving T-cell receptors
WO2007044033A2 (en) *	2004-12-07	2007-04-19	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
GB0427585D0 (en) *	2004-12-16	2005-01-19	Avidex Ltd	Assay
LT2275441T (lt)	2005-04-01	2016-12-12	Immunocore Ltd.	Dideliu afiniškumu pasižymintys živ t ląstelių receptoriai
CA2606287A1 (en)	2005-05-13	2006-11-16	Oxford Biomedica (Uk) Limited	Peptide
GB0510627D0 (en)	2005-05-25	2005-06-29	Avidex Ltd	Polypeptides
CN101309934B (zh) *	2005-08-31	2014-02-12	悉生物有限公司	修饰的伴侣蛋白10
US20090061478A1 (en) *	2006-01-30	2009-03-05	Lene Have Poulsen	High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
WO2007117588A2 (en) *	2006-04-05	2007-10-18	The General Hospital Corporation	Soluble virus-specific t-cell receptor compositions
US8088379B2 (en)	2006-09-26	2012-01-03	The United States Of America As Represented By The Department Of Health And Human Services	Modified T cell receptors and related materials and methods
JP5484041B2 (ja) *	2007-02-23	2014-05-07	学校法人関西学院	蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
KR101773690B1 (ko)	2007-03-05	2017-08-31	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
AU2013206501B2 (en) *	2007-03-05	2016-05-19	International Institute Of Cancer Immunology, Inc.	Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
WO2008116468A2 (en)	2007-03-26	2008-10-02	Dako Denmark A/S	Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (de)	2007-07-03	2025-02-19	Dako Denmark A/S	Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en)	2007-09-27	2020-04-07	Agilent Technologies, Inc.	MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da)	2008-02-28	2019-09-09	Dako Denmark As	MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en)	2008-07-23	2010-01-28	Dako Denmark A/S	Combinatorial analysis and repair
US8748170B2 (en)	2008-07-25	2014-06-10	University of Pittsburgh—of the Commonwealth System of Higher Education	Polypeptides derived from cyclin B1 and uses thereof
GB0817244D0 (en)	2008-09-20	2008-10-29	Univ Cardiff	Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en)	2008-10-02	2024-05-28	Agilent Technologies, Inc.	Molecular vaccines for infectious disease
WO2010037402A1 (en)	2008-10-02	2010-04-08	Dako Denmark A/S	Molecular vaccines for infectious disease
GB0908613D0 (en) *	2009-05-20	2009-06-24	Immunocore Ltd	T Cell Reseptors
EP3366692A1 (de)	2009-06-22	2018-08-29	Amgen, Inc	Proteinneufaltung mit einem chemisch gesteuerten redoxzustand
AU2010266093B2 (en)	2009-06-25	2013-06-27	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
GB0911566D0 (en) *	2009-07-03	2009-08-12	Immunocore Ltd	T cell receptors
EP2486049A1 (de)	2009-10-06	2012-08-15	The Board Of Trustees Of The UniversityOf Illinois	Menschliche einkettige t-zell-rezeptoren
GB201002730D0 (en) *	2010-02-18	2010-04-07	Uni I Oslo	Product
EP2694709B1 (de)	2011-04-08	2016-09-14	Prognosys Biosciences, Inc.	Peptidkonstrukte und testsysteme dafür
CA2839663A1 (en) *	2011-06-28	2013-01-03	International Institute Of Cancer Immunology, Inc.	Receptor gene for peptide cancer antigen-specific t cell
CN104334741B (zh)	2012-03-28	2018-08-17	歌德塔有限公司	组合的γ9δ2T细胞受体链交换
KR102499753B1 (ko)	2012-07-27	2023-02-16	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	Ｔ 세포 수용체 조작
US9561266B2 (en)	2012-08-31	2017-02-07	University Of Virginia Patent Foundation	Target peptides for immunotherapy and diagnostics
WO2014039675A2 (en)	2012-09-05	2014-03-13	University Of Virginia Patent Foundation	Target peptides for colorectal cancer therapy and diagnostics
HK1216153A1 (zh)	2012-12-13	2016-10-21	University Of Virginia Patent Foundation	用於卵巢癌治疗和诊断的靶向肽
EP4282419A1 (de)	2012-12-20	2023-11-29	Purdue Research Foundation	Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
GB201223172D0 (en)	2012-12-21	2013-02-06	Immunocore Ltd	Method
EP3736573A1 (de) *	2013-03-15	2020-11-11	Prognosys Biosciences, Inc.	Verfahren zum nachweis von peptid/mhc/tcr-bindung
KR102415259B1 (ko)	2013-11-22	2022-06-30	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	조작된 고-친화도의 인간 t 세포 수용체
EP3083674B1 (de)	2013-12-19	2018-10-03	Friedrich-Alexander-Universität Erlangen-Nürnberg	Grippenspezifischer t-zellenrezeptor und seine verwendung bei der erkennung, prävention und/oder behandlung von grippe
NZ724320A (en)	2014-03-14	2022-05-27	Adaptimmune Ltd	Tcr libraries
EP3137100B1 (de)	2014-04-15	2023-12-20	University Of Virginia Patent Foundation	Isolierte t-zellenrezeptoren und verfahren zur verwendung davon
GB201409558D0 (en) *	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
CN106279404A (zh) *	2015-05-20	2017-01-04	广州市香雪制药股份有限公司	一种可溶且稳定的异质二聚tcr
CA2995103A1 (en)	2015-08-07	2017-02-16	University Of Virginia Patent Foundation	Identification of class i mhc associated glycopeptides as targets for cancer immunotherapy
GB201514875D0 (en) *	2015-08-20	2015-10-07	Autolus Ltd	Receptor
US20190119350A1 (en)	2015-09-09	2019-04-25	Immune Design Corp.	Ny-eso-1 specific tcrs and methods of use thereof
GB201516272D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
GB201516277D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR libraries
GB201516265D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
GB201516270D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
GB201516275D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
GB201516274D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
GB201516269D0 (en)	2015-09-15	2015-10-28	Adaptimmune Ltd And Immunocore Ltd	TCR Libraries
DK3399985T3 (da)	2016-01-06	2022-03-21	Health Research Inc	Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer
KR20250071286A (ko)	2016-01-10	2025-05-21	네오티엑스 테라퓨틱스 엘티디.	면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
US20190161530A1 (en) *	2016-04-07	2019-05-30	Bluebird Bio, Inc.	Chimeric antigen receptor t cell compositions
US20190136230A1 (en)	2016-05-06	2019-05-09	Juno Therapeutics, Inc.	Genetically engineered cells and methods of making the same
US11827688B2 (en)	2016-06-02	2023-11-28	Immunocore Limited	Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
EP4099015A1 (de) *	2016-06-10	2022-12-07	Gadeta B.V.	Neuartiges verfahren zur identifizierung von delta-t-zell (oder gamma-t-zell)-rezeptorketten oder teilen davon, die eine antitumor- oder antiinfektionsreaktion vermitteln
EP3475706B1 (de) *	2016-06-27	2021-08-11	Juno Therapeutics, Inc.	Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
US20200182884A1 (en)	2016-06-27	2020-06-11	Juno Therapeutics, Inc.	Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MX2019003768A (es)	2016-10-03	2019-06-24	Juno Therapeutics Inc	Moleculas de enlace especificas de hpv.
JP7623784B2 (ja)	2016-10-13	2025-01-29	ジュノーセラピューティクスインコーポレイテッド	トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
JP2019532997A (ja)	2016-11-03	2019-11-14	ジュノーセラピューティクスインコーポレイテッド	Ｔ細胞療法とｂｔｋ阻害剤との併用療法
WO2018093591A1 (en)	2016-11-03	2018-05-24	Juno Therapeutics, Inc.	Combination therapy of a cell based therapy and a microglia inhibitor
CA3045339A1 (en)	2016-12-03	2018-06-07	Juno Therapeutics, Inc.	Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
BR112019011065A2 (pt)	2016-12-03	2019-10-01	Juno Therapeutics Inc	métodos para determinação da dosagem de células t car
CN110248678A (zh)	2016-12-03	2019-09-17	朱诺治疗学股份有限公司	调节car-t细胞的方法
KR20190098747A (ko)	2016-12-05	2019-08-22	주노 쎄러퓨티크스 인코퍼레이티드	입양 세포 치료법을 위한 조작된 세포의 제조방법
MX2019008227A (es)	2017-01-10	2020-08-17	Juno Therapeutics Inc	Analisis epigenetico de terapia celular y metodos relacionados.
CA3050085A1 (en)	2017-01-20	2018-07-26	Juno Therapeutics Gmbh	Cell surface conjugates and related cell compositions and methods
MX2019008840A (es)	2017-01-25	2019-09-09	Molecular Templates Inc	Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
US11649288B2 (en)	2017-02-07	2023-05-16	Seattle Children's Hospital	Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018148180A2 (en)	2017-02-07	2018-08-16	Immune Design Corp.	Materials and methods for identifying and treating cancer patients
MX2019009552A (es)	2017-02-17	2019-10-02	Hutchinson Fred Cancer Res	Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
BR112019017767A2 (pt)	2017-02-27	2020-04-07	Juno Therapeutics Inc	composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
WO2018160622A1 (en)	2017-02-28	2018-09-07	Endocyte, Inc.	Compositions and methods for car t cell therapy
MX2019010906A (es)	2017-03-14	2020-02-12	Juno Therapeutics Inc	Metodos para almacenamiento criogenico.
MX2019012017A (es)	2017-04-07	2020-02-12	Juno Therapeutics Inc	Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
CA3059584A1 (en)	2017-04-14	2018-10-18	Juno Therapeutics, Inc.	Methods for assessing cell surface glycosylation
CN118948892A (zh)	2017-05-01	2024-11-15	朱诺治疗学股份有限公司	细胞疗法与免疫调节化合物的组合
EP3624823A1 (de)	2017-05-18	2020-03-25	UMC Utrecht Holding B.V.	Zusammensetzungen und verfahren für zellgerichtete therapien
CN107216371B (zh) *	2017-05-27	2020-09-18	浙江师范大学	一种成人t细胞白血病的特异性靶向多肽及其应用
AU2018275894B2 (en)	2017-06-02	2025-04-24	Juno Therapeutics, Inc.	Articles of manufacture and methods for treatment using adoptive cell therapy
MA48781A (fr)	2017-06-02	2020-04-08	Juno Therapeutics Inc	Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
JP2020526194A (ja)	2017-06-29	2020-08-31	ジュノーセラピューティクスインコーポレイテッド	免疫療法薬と関連する毒性を評価するためのマウスモデル
SG11202000606TA (en)	2017-07-29	2020-02-27	Juno Therapeutics Inc	Reagents for expanding cells expressing recombinant receptors
KR20250016455A (ko)	2017-08-09	2025-02-03	주노 쎄러퓨티크스 인코퍼레이티드	유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
EP3664835B1 (de)	2017-08-09	2024-10-23	Juno Therapeutics, Inc.	Verfahren und zusammensetzungen zur herstellung genetisch veränderter zellen
WO2019046832A1 (en)	2017-09-01	2019-03-07	Juno Therapeutics, Inc.	GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
MA50079A (fr)	2017-09-07	2020-07-15	Juno Therapeutics Inc	Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
JP2020537515A (ja)	2017-10-03	2020-12-24	ジュノーセラピューティクスインコーポレイテッド	Ｈｐｖ特異的結合分子
JP2021500878A (ja)	2017-10-12	2021-01-14	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	免疫療法のためのｔ細胞受容体
US12258580B2 (en)	2017-11-01	2025-03-25	Juno Therapeutics, Inc.	Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
WO2019089884A2 (en)	2017-11-01	2019-05-09	Editas Medicine, Inc.	Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
US11851679B2 (en)	2017-11-01	2023-12-26	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
EP3704229B1 (de)	2017-11-01	2023-12-20	Juno Therapeutics, Inc.	Verfahren zur herstellung einer t-zell-zusammensetzung
US11564946B2 (en)	2017-11-01	2023-01-31	Juno Therapeutics, Inc.	Methods associated with tumor burden for assessing response to a cell therapy
EP3707258A1 (de)	2017-11-06	2020-09-16	Editas Medicine, Inc.	Verfahren, zusammensetzungen und komponenten zum crispr-cas9-editing von cblb in t-zellen zur immuntherapie
MX2020004568A (es)	2017-11-06	2020-10-05	Juno Therapeutics Inc	Combinación de una terapia celular y un inhibidor de gamma secretasa.
GB201719169D0 (en)	2017-11-20	2018-01-03	Univ College Cardiff Consultants Ltd	Novel T-cell receptor and ligand
MA51210A (fr)	2017-12-01	2020-10-07	Juno Therapeutics Inc	Procédés de dosage et de modulation de cellules génétiquement modifiées
MX2020005907A (es)	2017-12-08	2020-10-19	Juno Therapeutics Inc	Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
US12161670B2 (en)	2017-12-08	2024-12-10	Juno Therapeutics, Inc.	Phenotypic markers for cell therapy and related methods
CN119193493A (zh)	2017-12-08	2024-12-27	朱诺治疗学股份有限公司	生产工程化t细胞组合物的过程
US11311576B2 (en)	2018-01-22	2022-04-26	Seattle Children's Hospital	Methods of use for CAR T cells
JP7181517B2 (ja) *	2018-01-23	2022-12-01	国立大学法人三重大学	Ｔ細胞レセプター
JP7383620B2 (ja)	2018-01-31	2023-11-20	セルジーンコーポレイション	養子細胞療法およびチェックポイント阻害剤を使用する併用療法
US12312416B2 (en)	2018-02-06	2025-05-27	Seattle Children's Hospital	Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
AU2019225174B2 (en)	2018-02-23	2025-11-20	Endocyte, Inc.	Sequencing method for CAR T cell therapy
CA3094468A1 (en)	2018-04-05	2019-10-10	Juno Therapeutics, Inc.	Methods of producing cells expressing a recombinant receptor and related compositions
EP3773908A1 (de)	2018-04-05	2021-02-17	Juno Therapeutics, Inc.	T-zell-rezeptoren und gentechnisch veränderte zellen zur expression davon
MA52207A (fr)	2018-04-05	2021-02-17	Editas Medicine Inc	Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
WO2020018715A1 (en) *	2018-07-17	2020-01-23	Massachusetts Institute Of Technology	Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
US12516099B2 (en)	2018-08-09	2026-01-06	Juno Therapeutics, Inc.	Processes for generating engineered cells and compositions thereof
CN112805378A (zh)	2018-08-09	2021-05-14	朱诺治疗学股份有限公司	用于评估整合核酸的方法
SG11202102108QA (en)	2018-09-11	2021-04-29	Juno Therapeutics Inc	Methods for mass spectrometry analysis of engineered cell compositions
US20210380661A1 (en) *	2018-10-16	2021-12-09	Texas Tech University System	Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
WO2020086647A1 (en)	2018-10-23	2020-04-30	Regeneron Pharmaceuticals, Inc.	Ny-eso-1 t cell receptors and methods of use thereof
SG11202104355SA (en)	2018-10-31	2021-05-28	Juno Therapeutics Gmbh	Methods for selection and stimulation of cells and apparatus for same
AU2019371462A1 (en) *	2018-11-02	2021-05-20	University Of Washington	Orthogonal protein heterodimers
ES2968737T3 (es)	2018-11-06	2024-05-13	Juno Therapeutics Inc	Proceso para producir células T manipuladas genéticamente
CA3117978A1 (en)	2018-11-08	2020-05-14	Juno Therapeutics, Inc.	Methods and combinations for treatment and t cell modulation
PT3886875T (pt)	2018-11-30	2024-06-27	Juno Therapeutics Inc	Métodos para tratamento utilizando terapia celular adotiva
CN113692285A (zh)	2018-11-30	2021-11-23	朱诺治疗学股份有限公司	在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
WO2020127222A2 (en)	2018-12-17	2020-06-25	Immudex Aps	Panel comprising borrelia mhc multimers
WO2020223535A1 (en)	2019-05-01	2020-11-05	Juno Therapeutics, Inc.	Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CA3139899A1 (en)	2019-05-15	2020-11-19	Neotx Therapeutics Ltd.	Cancer treatment
CN114207136A (zh)	2019-06-07	2022-03-18	朱诺治疗学股份有限公司	自动化t细胞培养
KR20220034782A (ko)	2019-06-12	2022-03-18	주노 쎄러퓨티크스 인코퍼레이티드	세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
US12480958B2 (en)	2019-08-13	2025-11-25	Immatics Biotechnologies Gmbh	Method for the characterization of peptide:MHC binding polypeptides
CN114555112A (zh)	2019-08-22	2022-05-27	朱诺治疗学股份有限公司	T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
KR20220101641A (ko)	2019-10-30	2022-07-19	주노 테라퓨틱스 게엠베하	세포 선택 및/또는 자극 장치 및 사용 방법
MX2022006715A (es)	2019-12-06	2022-09-23	Juno Therapeutics Inc	Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
EP4093753A1 (de)	2020-01-24	2022-11-30	Regeneron Pharmaceuticals, Inc.	Bevorzugt exprimierte antigene in melanomen (prame) t-zell-rezeptoren und verfahren zur verwendung davon
JP2023512209A (ja)	2020-01-28	2023-03-24	ジュノーセラピューティクスインコーポレイテッド	Ｔ細胞形質導入のための方法
CN115210252A (zh)	2020-02-04	2022-10-18	西雅图儿童医院（Dba西雅图儿童研究所）	抗二硝基苯酚的嵌合抗原受体
CN115484978A (zh)	2020-03-05	2022-12-16	尼奥克斯医疗有限公司	使用免疫细胞治疗癌症的方法和组合物
KR20230024283A (ko)	2020-05-13	2023-02-20	주노 쎄러퓨티크스 인코퍼레이티드	임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
CN115835873A (zh)	2020-05-13	2023-03-21	朱诺治疗学股份有限公司	用于产生表达重组受体的供体分批细胞的方法
US20210403528A1 (en) *	2020-05-21	2021-12-30	University College Cardiff Consultants Ltd.	Novel T-Cell Receptor and Ligand
JP2023531531A (ja)	2020-06-26	2023-07-24	ジュノセラピューティクスゲーエムベーハー	組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
WO2022060904A1 (en)	2020-09-16	2022-03-24	Obsidian Therapeutics, Inc.	Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
KR20230112632A (ko)	2020-10-23	2023-07-27	애셔 바이오테라퓨틱스, 인크.	면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022133030A1 (en)	2020-12-16	2022-06-23	Juno Therapeutics, Inc.	Combination therapy of a cell therapy and a bcl2 inhibitor
CN117693508A (zh)	2021-03-03	2024-03-12	朱诺治疗学股份有限公司	T细胞疗法和dgk抑制剂的组合
AU2022241654A1 (en)	2021-03-22	2023-09-28	Juno Therapeutics, Inc.	Methods of determining potency of a therapeutic cell composition
CN117858719A (zh)	2021-03-29	2024-04-09	朱诺治疗学股份有限公司	使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
JP2024517863A (ja)	2021-05-06	2024-04-23	ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	細胞を刺激し、形質導入する方法
US20240336660A1 (en) *	2021-07-09	2024-10-10	The Johns Hopkins University	Method for surface expression of membrane proteins that have a cytoplasmic c-terminal tail
KR20240137075A (ko)	2022-01-28	2024-09-19	주노 쎄러퓨티크스 인코퍼레이티드	세포 조성물의 제조 방법
US20250297282A1 (en)	2022-05-05	2025-09-25	Juno Therapeutics Gmbh	Viral-binding protein and related reagents, articles, and methods of use
US20250345432A1 (en)	2022-05-25	2025-11-13	Celgene Corporation	Method for predicting response to a t cell therapy
EP4547230A1 (de)	2022-06-29	2025-05-07	Juno Therapeutics, Inc.	Lipidnanopartikel zur abgabe von nukleinsäuren
EP4583876A1 (de)	2022-09-08	2025-07-16	Juno Therapeutics, Inc.	Kombination einer t-zell-therapie und kontinuierlicher oder intermittierender dgk-hemmerdosierung
JP2026509947A (ja)	2022-10-31	2026-03-26	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法
WO2024100604A1 (en)	2022-11-09	2024-05-16	Juno Therapeutics Gmbh	Methods for manufacturing engineered immune cells
WO2024124132A1 (en)	2022-12-09	2024-06-13	Juno Therapeutics, Inc.	Machine learning methods for predicting cell phenotype using holographic imaging
CN120731219A (zh) *	2022-12-23	2025-09-30	天科雅生物科技有限公司	用于改善工程化免疫细胞中免疫应答的组合物和方法
JP2026504491A (ja)	2023-02-03	2026-02-05	ツェー３エス２ゲーエムベーハー	操作された免疫細胞の非ウイルス的製造のための方法
CN120882754A (zh)	2023-04-07	2025-10-31	瑞泽恩制药公司	用淋巴毒素β受体激动剂治疗癌症的方法
WO2024220588A1 (en)	2023-04-18	2024-10-24	Juno Therapeutics, Inc.	Cytotoxicity assay for assessing potency of therapeutic cell compositions
KR20260026101A (ko)	2023-05-23	2026-02-25	주노 쎄러퓨티크스 인코퍼레이티드	T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
EP4720109A1 (de)	2023-05-25	2026-04-08	Regeneron Pharmaceuticals, Inc.	T-zell-rezeptoren, die präsentierte hpv16-, mart1-, cmv-, ebv- oder influenza-peptide binden
WO2025133340A1 (en) *	2023-12-21	2025-06-26	Ludwig Institute For Cancer Research Ltd	Heterodimeric proteins comprising dimerization motifs and methods of using
WO2025147545A1 (en)	2024-01-03	2025-07-10	Juno Therapeutics, Inc.	Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025226775A2 (en) *	2024-04-23	2025-10-30	New York University	Compositions and methods for binding to covalent peptide conjugates
WO2026025092A1 (en)	2024-07-26	2026-01-29	Juno Therapeutics, Inc.	Synthetic promoters for t cell expression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5620689A (en) *	1989-10-20	1997-04-15	Sequus Pharmaceuuticals, Inc.	Liposomes for treatment of B-cell and T-cell disorders
US5216132A (en) *	1990-01-12	1993-06-01	Protein Design Labs, Inc.	Soluble t-cell antigen receptor chimeric antigens
US5582996A (en) *	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
DE4040669A1 (de) *	1990-12-19	1992-06-25	Behringwerke Ag	Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik
US5328985A (en) *	1991-07-12	1994-07-12	The Regents Of The University Of California	Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
AR246435A1 (es) *	1992-08-20	1994-08-31	Moreno Saul	Jeringa descartable para uso con cubreagujas
WO1996021028A2 (en) *	1995-01-03	1996-07-11	Procept, Inc.	Soluble heterodimeric t cell receptors and their antibodies
US5635363A (en) *	1995-02-28	1997-06-03	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5968511A (en) *	1996-03-27	1999-10-19	Genentech, Inc.	ErbB3 antibodies
NZ331688A (en) *	1996-03-28	2000-02-28	Univ Johns Hopkins	Soluble divalent and multivalent heterodimeric analogs of proteins
US5776746A (en) *	1996-05-01	1998-07-07	Genitope Corporation	Gene amplification methods
JP2000516470A (ja) *	1996-08-16	2000-12-12	プレジデントアンドフェローズオブハーバードカレッジ	可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用
WO1999060120A2 (en) *	1998-05-19	1999-11-25	Avidex Limited	Soluble t cell receptor

1999
- 1999-05-19 WO PCT/GB1999/001588 patent/WO1999060120A2/en not_active Ceased
- 1999-05-19 DE DE69900468T patent/DE69900468T2/de not_active Expired - Fee Related
- 1999-05-19 NZ NZ507887A patent/NZ507887A/xx unknown
- 1999-05-19 KR KR10-2000-7012879A patent/KR100530309B1/ko not_active Expired - Fee Related
- 1999-05-19 CA CA002328144A patent/CA2328144A1/en not_active Abandoned
- 1999-05-19 EP EP99922355A patent/EP1080193A2/de not_active Withdrawn
- 1999-05-19 AU AU39456/99A patent/AU758949B2/en not_active Ceased
- 1999-05-19 PT PT99922360T patent/PT1066380E/pt unknown
- 1999-05-19 HU HU0103614A patent/HUP0103614A2/hu unknown
- 1999-05-19 HR HR20000790A patent/HRP20000790A2/hr not_active Application Discontinuation
- 1999-05-19 AT AT99922360T patent/ATE208819T1/de not_active IP Right Cessation
- 1999-05-19 EP EP99922360A patent/EP1066380B1/de not_active Expired - Lifetime
- 1999-05-19 JP JP2000549727A patent/JP2002515243A/ja not_active Withdrawn
- 1999-05-19 NZ NZ507886A patent/NZ507886A/en unknown
- 1999-05-19 BR BR9910253-6A patent/BR9910253A/pt not_active IP Right Cessation
- 1999-05-19 CA CA002327314A patent/CA2327314A1/en not_active Abandoned
- 1999-05-19 ES ES99922360T patent/ES2168866T3/es not_active Expired - Lifetime
- 1999-05-19 PL PL99364734A patent/PL364734A1/xx unknown
- 1999-05-19 IL IL13934499A patent/IL139344A0/xx unknown
- 1999-05-19 ID IDW20002387A patent/ID28040A/id unknown
- 1999-05-19 DK DK99922360T patent/DK1066380T3/da active
- 1999-05-19 EA EA200001216A patent/EA200001216A1/ru unknown
- 1999-05-19 WO PCT/GB1999/001583 patent/WO1999060119A2/en not_active Ceased
- 1999-05-19 AU AU39459/99A patent/AU746164B2/en not_active Ceased
- 1999-05-19 KR KR1020007012844A patent/KR20010085250A/ko not_active Ceased
- 1999-05-19 JP JP2000549728A patent/JP2002515244A/ja active Pending
- 1999-05-19 TR TR2000/03391T patent/TR200003391T2/xx unknown
- 1999-05-19 CN CNB998076082A patent/CN1249229C/zh not_active Expired - Fee Related
- 1999-05-19 CN CN99808473A patent/CN1308674A/zh active Pending
- 1999-05-19 IL IL13934599A patent/IL139345A0/xx unknown
- 1999-05-19 EE EEP200000697A patent/EE200000697A/xx unknown
- 1999-05-19 SK SK1733-2000A patent/SK17332000A3/sk unknown
2000
- 2000-10-31 IS IS5697A patent/IS5697A/is unknown
- 2000-11-17 NO NO20005812A patent/NO20005812L/no not_active Application Discontinuation
- 2000-11-17 NO NO20005811A patent/NO20005811L/no unknown
- 2000-12-14 BG BG105053A patent/BG105053A/bg unknown
2001
- 2001-07-25 US US09/912,787 patent/US20020119149A1/en not_active Abandoned
- 2001-11-13 US US10/014,326 patent/US20020142389A1/en not_active Abandoned
2005
- 2005-06-27 US US11/167,773 patent/US20060093613A1/en not_active Abandoned
- 2005-12-29 US US11/321,894 patent/US20060155115A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2328144A1 (en)	1999-11-25
PT1066380E (pt)	2002-05-31
WO1999060120A3 (en)	2000-02-03
DK1066380T3 (da)	2002-01-28
IL139344A0 (en)	2001-11-25
NO20005811L (no)	2001-01-19
CA2327314A1 (en)	1999-11-25
NO20005812D0 (no)	2000-11-17
WO1999060119A2 (en)	1999-11-25
BG105053A (bg)	2001-09-28
IS5697A (is)	2000-10-31
KR20010043675A (ko)	2001-05-25
KR100530309B1 (ko)	2005-11-22
NO20005812L (no)	2001-01-19
NO20005811D0 (no)	2000-11-17
HUP0103614A2 (hu)	2002-01-28
AU746164B2 (en)	2002-04-18
DE69900468D1 (de)	2001-12-20
EP1066380A2 (de)	2001-01-10
JP2002515244A (ja)	2002-05-28
HRP20000790A2 (en)	2001-06-30
AU3945999A (en)	1999-12-06
US20060093613A1 (en)	2006-05-04
EE200000697A (et)	2002-06-17
CN1249229C (zh)	2006-04-05
WO1999060119A3 (en)	2000-02-03
ATE208819T1 (de)	2001-11-15
AU3945699A (en)	1999-12-06
ID28040A (id)	2001-05-03
NZ507887A (en)	2002-12-20
US20020119149A1 (en)	2002-08-29
KR20010085250A (ko)	2001-09-07
ES2168866T3 (es)	2002-06-16
AU758949B2 (en)	2003-04-03
NZ507886A (en)	2003-05-30
WO1999060120A2 (en)	1999-11-25
EP1080193A2 (de)	2001-03-07
JP2002515243A (ja)	2002-05-28
CN1308674A (zh)	2001-08-15
EA200001216A1 (ru)	2001-06-25
TR200003391T2 (tr)	2001-02-21
HK1035739A1 (en)	2001-12-07
CN1306572A (zh)	2001-08-01
IL139345A0 (en)	2001-11-25
US20020142389A1 (en)	2002-10-03
EP1066380B1 (de)	2001-11-14
BR9910253A (pt)	2002-09-17
US20060155115A1 (en)	2006-07-13
PL364734A1 (en)	2004-12-13
DE69900468T2 (de)	2002-07-18

Publication	Publication Date	Title
SK17332000A3 (sk)	2001-06-11	Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby
EP3850363B1 (de)	2025-01-22	Hochdurchsatz-screeningmethoden für t-zell rezeptor liganden durch bestimmung von peptid-mhc affinitäten zu t-zell rezeptoren auf der basis von stabilisierten, peptid-freien mhc-komplexen
JP4436319B2 (ja)	2010-03-24	単鎖組換えｔ細胞レセプター
CN114423284A (zh)	2022-04-29	T细胞调节多肽及其使用方法
JP2007511760A (ja)	2007-05-10	Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
Le Gall et al.	2022	Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
CN107847544B (zh)	2021-10-15	用多聚体结合试剂检测细胞表型和定量
AU2020299989A1 (en)	2022-02-17	Peptide-MHC complexes
Baker et al.	2001	αβ T cell receptor ligand-specific oligomerization revisited
Pecorari et al.	1999	Folding, heterodimeric association and specific peptide recognition of a murine αβ T-cell receptor expressed in Escherichia coli
Tissot et al.	2000	Characterizing the functionality of recombinant T-cell receptors in vitro: a pMHC tetramer based approach
HK1035739B (en)	2002-07-26	Soluble t cell receptor
ZA200006181B (en)	2002-01-31	Soluble T cell receptor.
Garner et al.	2006	Expression, purification, and refolding of the myeloid inhibitory receptor leukocyte immunoglobulin-like receptor-5 for structural and ligand identification studies
CZ20004214A3 (cs)	2001-04-11	Rozpustný receptor T buněk
MXPA00011367A (en)	2002-07-25	Soluble t cell receptor
MXPA00011368A (en)	2002-07-25	Multivalent t cell receptor complexes
Kim et al.	2009	Use of Peptoid-Peptide Hybrids in the Development of Shc SH2 Domain–Binding Inhibitors